I disagree that the facility is the money maker. That simply doesn't make any business sense. It might be an hors d'oeuvre, but not the main course. The facility simply cannot add several multiples of the current worth of the company.
This is a generic company with generic multiples. We cannot forget that. That's the basis on which an acquirer will value it using actuals and forecasted projections, with current products and the pipeline, assets (incl facilities), etc.
Also, remember that the last valuation done was when the pipeline was basically a ton of branded drugs Elite was going to pump out at lightning speed. That path failed and led to a ton of dilution. Not an apples-to-apples comparison anymore.
When an acquirer buys a company there are advantages, synergies, dissynergies, pros and cons, some financial, some not. Just because an acquirer will benefit from a synergy (what attracts them to buy to begin with) does not mean that that translates to the benefit of the owners in the buyout price. That's part of the benefit and value to be gained by the buyer. If shareholders gained all of the buyer's value & creation, the whole deal wouldn't be worth pursuing.
That would be like you selling me land and then wanting the capture the rent revenue for the condos I am going to build.
Just trying to keep the expectations grounded. Lots of assumptions being thrown out this week that are pretty wild.
Market Data 
Markets 
AI
